Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments. Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles: A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia.
Study Type
OBSERVATIONAL
Enrollment
600
Additional blood samples for biobanking
Hôpital Roger Salengro, CHU
Lille, France
RECRUITINGFrequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES)
The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.
Time frame: 10 years
Frequency of the evolutionary profiles
Frequency of the different evolutionary profiles.
Time frame: 10 years
Frequency of complications depending of the type of HES
Frequency of complications (organ damages) depending on the type of HES (idiopathic, reactive, clonal…).
Time frame: 10 years
Frequency of organ damage profiles before and after 18 years old.
Describe the characteristics of pediatrics HE/HES vs adult HE/HES.
Time frame: 10 years
Frequency of clinical complications profiles before and after 18 years old.
Clinical characteristics of pediatrics HE/HES vs adult HE/HES.
Time frame: 10 years
Frequency of HLA alleles and variants / mutations on other genes of HE/HES
Predisposing factors in HE/HES by various genomic approaches
Time frame: 10 years
Serum biomarkers
to explore Potential predisposing factors in HE/HES: serum markers predictive of interest in eosinophilopoiesis (IL5), tissue homing (eotaxins, etc.)
Time frame: 10 years
Difference in Membrane activation markers of HE patients (asymptomatic) versus SHE (symptomatic).
Predisposing factors in HE/HES by various genomic approaches
Time frame: 10 years
Difference in Eosinophilic gene expression profiles of HE patients (asymptomatic) versus SHE (symptomatic).
Predisposing factors in HE/HES by various genomic approaches
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.